Ja
Non verificato

Janux Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza
23/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
1.00
01/12/2025
Web e Social Network
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
1.00
06/11/2025
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
1.00
07/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Mercato azionario
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
1.00
05/08/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
1.00
24/07/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Web e Social Network
Industria
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
1.00
17/07/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
1.00
15/05/2025
Mercato del lavoro
Oncologia
Salute
Sanità
Farmaceutica
Biotecnologia
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0